aTyr Pharma sees 80% share price drop, investors launch fraud investigation.

aTyr Pharma's late-stage study of efzofitimod for treating pulmonary sarcoidosis failed to meet its main goal, causing a significant drop in share price. National shareholders rights firm Hagens Berman is investigating whether the company misled investors about Phase 2 data and the Phase 3 EFZO-FIT trial design. Investors who suffered losses are encouraged to submit their losses and those with knowledge to contact the firm.